LoadingLoadingLoadingThe quick read
Latest quote·Oct 16
Net selling: insiders sold $96K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNet selling: insiders sold $96K and bought $0 of A stock on the open market in the 90 days to Oct 18, 2026, according to SEC Form 4 filings. The largest was Dolsten, Mikael (Director), who sold $96K. The latest filing was on Sep 9, 2026.
None. No member of Congress disclosed a A trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
This summary uses filings available on Oct 18, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position and insiders have been net selling.
Buys/Adds (1)
Glenview Capital
$261.6M
bought
Sells/Trims (2)
Balyasny
$74.5M
trimmed
Two Sigma
$74.1M
trimmed
Buys (1)
Sells (1)
No tracked top-trader positions in A right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Aug 26, 2026
Period ending
Jul 31, 2026
Earnings per share
$1.48 expected
Revenue
No reported revenue on record
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jul 31, 2026 | Aug 26, 2026 | $1.62 / $1.48Alpha Vantage | +9.46% beat | Unavailable | Unavailable |
| Apr 30, 2026 | May 27, 2026 | $1.49 / $1.41Alpha Vantage | +5.67% beat | $1.83B / Unavailable | Unavailable |
| Jan 31, 2026 | Feb 25, 2026 | $1.36 / $1.37Alpha Vantage | -0.73% in line | Unavailable | Unavailable |
| Oct 31, 2025 | Nov 24, 2025 | $1.59 / $1.58Alpha Vantage | +0.63% in line | Unavailable | Unavailable |
| Jul 31, 2025 | Aug 27, 2025 | $1.37 / $1.37Alpha Vantage | +0.00% in line | Unavailable | Unavailable |
| Apr 30, 2025 | May 28, 2025 | $1.31 / $1.26Alpha Vantage | +3.97% beat | Unavailable | Unavailable |
| Jan 31, 2025 | Feb 26, 2025 | $1.31 / $1.27Alpha Vantage | +3.15% beat | Unavailable | Unavailable |
| Oct 31, 2024 | Nov 25, 2024 | $1.46 / $1.41Alpha Vantage | +3.55% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Estimates as of Oct 17, 2026
EPS expected
$1.71 to $1.74
Revenue expected
16 analysts
Last 30 days
Split both ways
| USD | Oct 2025 | Jan 2026 | Apr 2026 | Jul 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.86B | $1.80B | $1.83B | $1.88B |
| Cost of what it sold | $897.0M | $852.0M | $826.0M | $836.0M |
| Gross profit | $964.0M | $946.0M | $1.01B | $1.04B |
| What it spent | ||||
| Research and development | $119.0M | $117.0M | $126.0M | $123.0M |
| Sales and admin | $428.0M | $476.0M | $465.0M | $475.0M |
| Other operating costs | -$26.0M | — | $19.0M | — |
| Total operating expenses | $521.0M | $593.0M | $610.0M | $598.0M |
| What was left | ||||
| Operating profit | $443.0M | $353.0M | $399.0M | $444.0M |
| Interest on debt | $27.0M | $25.0M | $25.0M | $29.0M |
| Profit before tax | $442.0M | $364.0M | $408.0M | $444.0M |
| Tax | $8.0M | $59.0M | $69.0M | $82.0M |
| Net profit | $434.0M | $305.0M | $339.0M | $362.0M |
| EBITDA | $540.0M | $456.0M | $500.0M | $539.0M |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
JPMorgan Adjusts Price Target on Agilent Technologies to $195 From $190
Leans bullishOct 15Bruker, Sotera downgraded as J.P. Morgan reviews life sciences coverage
NeutralOct 14Philly-based AI medical analysis start-up to be acquired for up to $270 million
BullishOct 14Agilent to buy Proscia for $240M
BullishOct 14Why Agilent Is Spending up to $270 Million on an AI Pathology Specialist
NeutralOct 14Agilent spends $240M upfront to buy digital pathology specialist Proscia
BullishOct 14Agilent to Acquire Proscia for Up to $270M to Build Scientific Intelligence Layer in Digital Pathology
BullishOct 14Agilent to expand capabilities in China
BullishOct 14